Aridis Pharmaceuticals, Inc.
ARDS · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -97.9% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -194.2% | 69.9% | – | – |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -19.9% | 61.8% | – | – |
| EPS Diluted | -0.002 | 0.33 | -0.22 | -0.35 |
| % Growth | -100.7% | 250% | 37.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |